Pieris Pharmaceuticals and Seattle Genetics Announce

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
248
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

BOSTON, MA and BOTHELL, WA --(Marketwired - February 09, 2018) - Pieris Pharmaceuticals, Inc. ( NASDAQ : PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc. ( NASDAQ : SGEN ), a global biotechnology company developing innovative, targeted therapies for cancer, today announced they have entered into a collaboration and license agreement with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers.

The collaboration leverages the expertise and core technologies of both companies to develop novel Antibody-Anticalin fusion proteins. Pieris' proprietary suite of agonistic costimulatory Anticalin proteins, when fused to a tumor-targeting antibody, can activate the immune system preferentially in the tumor microenvironment. Seattle Genetics, through its industry-leading work in the field of antibody-drug conjugates (ADCs), has a substantial portfolio of cancer targets and tumor-specific monoclonal antibodies from which programs will be selected for the collaboration. The bispecific drug candidates in this alliance will be designed to enable the patient's immune cells to specifically attack tumors.

"As the industry leader in ADCs, we bring deep expertise in targeted cancer therapy development to this collaboration with Pieris," said Dennis Benjamin, Ph.D., Senior Vice President of Research at Seattle Genetics. "Pieris' Anticalin technology and Antibody-Anticalin bispecific approach are intended to overcome the limitations of currently available immuno-oncology products. This partnership leverages our cancer targets and tumor-specific antibodies to explore multiple novel bispecific combinations, with the goal of developing targeted therapies that improve outcomes for people with cancer."

Under the terms of the agreement, Seattle Genetics will pay Pieris a $30 million upfront fee, tiered royalties on net sales up to low double-digits, and up to $1.2 billion in total success-based payments across three product candidates. The companies will pursue multiple Antibody-Anticalin fusion proteins during the research phase, and Seattle Genetics has the option to select up to three therapeutic programs for further development. Prior to the initiation of a pivotal trial, Pieris may opt into global co-development and US commercialization of the second program and share in global costs and profits on a 50/50 basis. Seattle Genetics will solely develop, fund and commercialize the other two programs.

"Pieris was the first company to bring a tumor-targeted costimulatory bispecific to patients with PRS-343, and we are looking forward to broadening our bispecific pipeline through this alliance. Seattle Genetics is a compelling partner for Pieris with a long-standing commitment to oncology," said Stephen S. Yoder, President and CEO of Pieris. "The collaboration combines the excellent protein engineering and translational capabilities of both companies, utilizing Seattle Genetics' tumor-targeted monoclonal antibodies and Pieris' Anticalin proteins to create novel bispecifics. This is our third significant alliance since January 2017 and is in alignment with our goal to create a respiratory- and oncology-focused commercial company."

About Anticalin® Therapeutics: Anticalin® proteins are derived from lipocalins, small human proteins that naturally bind, store and transport a wide spectrum of molecules. Anticalin® proteins feature the typical four-loop variable region and a rigidly conserved beta-barrel backbone of lipocalins, which, together, form a shapeable cup-like binding pocket. Proprietary to Pieris, Anticalin® proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin ® is a registered trademark of Pieris.

About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com .

For more information visit www.pieris.com .

About Seattle Genetics : Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company's industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Pieris Forward Looking Statements Disclaimer: This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; the timing and progress of our studies, including the timing of enrollment and dosing of PRS-343 patients and PRS-060 healthy subjects, the enrollment of patients in the PRS-080 multi-dose trial; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company's Quarterly Reports on Form 10-Q.

Seattle Genetics Forward Looking Statements Disclaimer: Certain of the statements made in this press release are forward looking, such as those, among others, relating to the research, development, and therapeutic and commercial potential of Anticalin-based products. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the possibility that the referenced product candidates may not be feasible to develop, may not show utility in treating cancer, may not have the desired activity or may be associated with adverse events that limit their use in which case Seattle Genetics may not realize the anticipated benefits from the collaboration. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption "Risk Factors" included in Exhibit 99.1 to the company's Current Report on Form 8-K filed with the Securities and Exchange Commission in January 31, 2018. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts at Pieris: Company Contact: Pieris Pharmaceuticals, Inc. Allan Reine SVP and Chief Financial Officer +1-857-444-4276 reine@pieris.com Investor Relations Contact: The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com Media Contact Trophic Communications Gretchen Schweitzer +49 89 238 87730 schweitzer@trophic.eu Contacts at Seattle Genetics: Investor Relations: Peggy Pinkston VP, Investor Relations 425-527-4160 ppinkston@seagen.com Media: Tricia Larson Sr Director, Corporate Communications 425-527-4180 tlarson@seagen.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 27

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 46

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
SeoulTech's Liver Chip Makes Toxicity Testing Practical

Updated Category News Views 32

A Lab Tool Finally Built for the Messy Part Thousands of everyday chemicals are floating around commerce with thin toxicity records, and that is a lousy way to run a modern economy. Seoul National University of Science and Technology researchers have put forward a modular liver-on-a-chip platform aimed squarely at that gap: making environmental chemical testing more...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 111

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 93

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Starbucks Workers Unite in Major Strike Action Ahead of Holidays

Updated Category News Views 645

Starbucks Workers Prepare for Significant Strike Starbucks (NASDAQ: SBUX) workers, represented by a union encompassing more than 10,000 individuals, have announced plans for a strike in major cities like Los Angeles, Chicago, and Seattle. This strike is set to commence on Friday and is expected to last through the busy Christmas season. Union's Demands for Better...

Continue Reading
Discover Häagen-Dazs® Summer Blueberry Collection Now!

Updated Category News Views 140

Häagen-Dazs® Shops Launches Delicious Summer Blueberry Collection The summer season is here, and Häagen-Dazs® Shops embraces it with their enticing Summer Blueberry Collection. This delightful selection is all about providing a refreshing and revitalizing experience for ice cream lovers. With an exquisite range of flavors, including the brand's first-ever oat...

Continue Reading
Innovative Beef Supply Chain By Rancher's Sustainable Angus Alliance

Updated Category News Views 240

Transforming the Beef Supply Chain for Sustainability The Rancher's Sustainable Angus Alliance (RSAA) is actively engaging with beef retail partners who are committed to delivering top-notch Angus beef while emphasizing animal welfare and environmental responsibility. Founded by a group of visionary seedstock ranchers, RSAA aims to connect consumers with the rich heritage...

Continue Reading
Emerging Trends and Growth in Global Glucose Testing Market

Updated Category News Views 131

Overview of the Global Point-of-Care Glucose Testing Market The Point-of-Care Glucose Testing Market is experiencing significant growth, fueled by increasing rates of diabetes globally and a shift towards more accessible healthcare solutions. As patients and healthcare providers seek easier and more accurate ways to manage diabetes, this market is expected to thrive,...

Continue Reading
Artesian Resources Corporation Celebrates Strong Growth in 2025

Updated Category News Views 182

Artesian Resources Corporation's Impressive Performance Artesian Resources Corporation (NASDAQ: ARTNA), a distinguished provider of water and wastewater services on the Delmarva Peninsula, has recently disclosed its remarkable financial performance for the third quarter and year-to-date of 2025. The reports reveal significant increases in both revenue and net income,...

Continue Reading